Brian Loring
Podiatrist · Augusta, MENPI 1457980096
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,893 of the $2,951 with a category attached, or 64.1%. Stryker accounts for 80.5% of it on its own, with 8 other manufacturers making up the rest.
Across 32 payments — averaging $92.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Novus Surgical Solutions LLC$144
- Averitas Pharma Inc.$119
- Treace Medical Concepts, Inc.$100
- Orthofix Medical, Inc.$86
- Acumed LLC$50
- plus $78 from 3 others
What the payments were for
- Travel & lodging$1,05836%
- Food & beverage$1,89364%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 18 | $2,374 |
| Novus Surgical Solutions LLC | 1 | $144 |
| Averitas Pharma Inc. | 5 | $119 |
| Treace Medical Concepts, Inc. | 1 | $100 |
| Orthofix Medical, Inc. | 3 | $86 |
| Acumed LLC | 1 | $50 |
| Novus Surgical Consultants | 1 | $36 |
| Vertex | 1 | $24 |
| Bioventus LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROstep$751
- INFINITY$669
- BIOFOAM$275
- N/A$216
- ALLOWRAP$117
- AUGMENT INJECTABLE$117
- HOFFMANN$117
- AXSOS$117
- Lapiplasty System$100
How this compares
$2,951 in reported general payments places this provider in the 75th percentile of 20 podiatrist providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 14 | $1,248 |
| Gabapentin | 76 | $1,232 |
| Terbinafine Hcl | 41 | $960 |
| Ciclopirox | 14 | $647 |
| Ammonium Lactate | 33 | $264 |
| Methylprednisolone | 15 | $103 |
| Cephalexin | 12 | $99 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $87 |
| Doxycycline Hyclate | 12 | $74 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Augusta
- Christopher TothBiddeford$10K
- Lance HopkinSkowhegan$7K
- Puneet ChahalBrunswick$7K
- Peter OcampoScarborough$6K
- Robert TaylorPortland$3K
- Jeffrey JohnsonRumford$2K
- Christopher SaccoLewiston$798
- Robert AndersonBrewer$425
- Shannon MeredithPortland$403
- Andrew LamPatten$369
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.